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Abstract
Background: Experimental autoimmune encephalomyelitis has been used extensively as an animal model of T cell
mediated autoimmunity. A down-regulatory pathway through which encephalitogenic CD4Th1 cells are killed by
CD8 regulatory T cells (Treg) has recently been proposed. With the CD8Treg cells being primed by dendritic cells,
regulation of recovery may be occuring around these antigen presenting cells. CD4Treg cells provide critical help
within this process, by licensing dendritic cells to prime CD8Treg cells, however the spatial and temporal aspects of
this help in the CTL response is currently unclear.
Results: We have previously developed a simulator of experimental autoimmune encephalomyelitis (ARTIMMUS).
We use ARTIMMUS to perform novel in silico experimentation regarding the priming of CD8Treg cells by dendritic
cells, and the resulting CD8Treg mediated killing of encephalitogenic CD4Th1 cells. Simulations using dendritic cells
that present antigenic peptides in a mutually exclusive manner (either MBP or TCR-derived, but not both) suggest
that there is no significant reliance on dendritic cells that can prime both encephalitogenic CD4Th1 and Treg cells.
Further, in silico experimentation suggests that dynamics of CD8Treg priming are significantly influenced through
their spatial competition with CD4Treg cells and through the timing of Qa-1 expression by dendritic cells.
Conclusion: There is no requirement for the encephalitogenic CD4Th1 cells and cytotoxic CD8Treg cells to be
primed by the same dendritic cells. We conjecture that no significant portion of CD4Th1 regulation by Qa-1
restricted CD8Treg cells occurs around individual dendritic cells, and as such, that CD8Treg mediated killing of
CD4Th1 cells occurring around dendritic cells is not critical for recovery from the murine autoimmune disease.
Furthermore, the timing of the CD4Treg licensing of dendritic cells and the spatial competition between CD4Treg
and CD8Treg cells around the dendritic cell is critical for the size of the cytotoxic T lymphocyte response, because
dendritic cells have a limited lifespan. If treatments can be found to either speed up the licensing process, or
increase the spatial competitiveness of CD8Treg cells, the magnitude of the cytotoxic T lymphocyte response can
be increased.
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Background
Under normal circumstances, self-tolerance mechanisms
ensure the host’s immune system does not react against
self antigens [1]. When these self-tolerance mechanisms
fail, autoimmune responses occur, which may culminate
in the development of autoimmune disease(s). Experi-
mental autoimmune encephalomyelitis (EAE) is an ani-
mal model of T cell mediated autoimmune diseases in
general, and multiple sclerosis (MS) in particular [2]. The
animal disease is mediated through a network of cells
(see Figure 1); encephalitogenic T helper cells are acti-
vated in the peripheral lymph nodes following immuniza-
tion for EAE, and migrate to the central nervous system
(CNS) where they induce activation of microglia, macro-
phages and dendritic cells (DCs) [3]. The resultant
inflammation causes demyelination of neurons, prompt-
ing the presentation of myelin basic protein (MBP) to
additional encephalitogenic T cell populations in the cer-
vical lymph nodes (CLN) by migratory DCs. The sponta-
neous recovery that occurs following autoimmune
episodes is associated with a major reduction in the T
cell infiltrate in the CNS [4]. Recent evidence indicates
that encephalitogenic CD4Th1 cells undergo selective
T cell mediated regulation; CD4 T regulatory cells
(CD4Treg) help DCs in priming CD8 T regulatory cells
(CD8Treg) that induce selective apoptotic elimination of
CD4Th1 cells [5,6]. The DCs mediate down-regulation of
the autoimmune response through the expression of
Qa-1 (a MHC class Ib molecule, first discovered by
Cantor et al [6]), which facilitates the priming of
CD8Treg cells, for subsequent killing of encephalitogenic
CD4Th1 cells [7].
The exact location of killing of the encephalitogenic
CD4Th1 cells, and thus down-regulation of the autoim-
mune response by CD8Treg cells, is unknown. One pos-
sibility is that DCs migrating from the CNS, potentially
carrying both MBP (from neurons) and T cell receptor
(TCR) derived peptides, are simultaneously priming both
CD4Th1 and Treg cell populations [8], and that regula-
tion of autoimmunity is taking place around the DC.
Effector CD4Th1 cells contain framework region 3 (Fr3)
and complementarity determining region 1/2 (CDR1/2)
peptides within their TCR molecules, and once efferocy-
tosed by a DC, there is a probabilistic chance that the DC
will present the Fr3 and CDR1/2 peptides on MHC class
II molecules. Tang et al [9] suggest that the CD8Treg
Figure 1 Cell network model of CD8Treg mediated regulation within the ARTIMMUS EAE simulator. Computer simulations commence
following immunization with MBP, which DCs subsequently engulf and present on MHC class II molecules to facilitate activation of MBP-specific
encephalitogenic CD4Th1 cells. Effector CD4Th1 cells migrate to the CNS and initiate the autoimmune pathway (red solid arrows) through microglia
induced killing of neurons (our computational abstraction of demyelination within EAE). Effector CD4Th1 cells undergo activation-induced cell death
at the end of the cell lifecycle. Apoptotic CD4Th1 cells migrate out of the CNS, and are efferocytosed by CLN and spleen-resident DCs. They may also
be efferocytosed in the CNS by DCs that migrate to the CLN upon maturation. These DCs present TCR peptides, which initiate the down-regulatory
pathway (blue dashed arrows) through activation of CD4Treg cells and CD8Treg cells [5], and subsequent killing of the encephalitogenic CD4Th1 cells.
On a population level, regulation of CD4Th1 cells leads to a type2 deviation [23], resulting in down-regulation of the autoimmune response. Adapted
from [20].
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response is cross-primed by DCs that have efferocytosed
apoptotic CD4Th1 cells and present TCR-derived pep-
tide to both CD4Treg and CD8Treg cells [8,10]. Kumar
and colleagues [11-13] found that CD4Treg cells may
then become activated by binding to the Fr3-MHCII
complex of an antigen presenting cell (e.g. DC or micro-
glia). Conversely, CD8Treg cells recognise TCR-derived
peptides relating to the CDR1/2 regions, which have
been cross-presented on MHC class I molecules.
The spatial and temporal features of EAE lend them-
selves well to being modelled using an agent-based
approach. In this paper we investigate the effect of regu-
lation of CD4Th1 cells by CD8Treg cells through use of
a simulation (ARTIMMUS), which we have previously
developed to support investigation into EAE [14]. We
investigate three hypotheses, the first hypothesis is that
a significant portion of CD4Th1 and CD8Treg cell
priming occurs simultaneously around the same DCs.
The second hypothesis (termed the age of licensing
hypothesis) is that the timing of Qa-1 expression by
DCs has a significant effect on the size of the CD8Treg
effector cell population. The third hypothesis (termed
the spatial saturation hypothesis) is that spatial compe-
tition between CD4Treg and CD8Treg cells around DCs
on which they prime, has a significant effect on the size
of the CD8Treg effector cell population. We have per-
formed a number of in silico experiments to further
understand the priming dynamics of CD8Treg cells by
DCs against these three hypotheses. In order to establish
control simulation dynamics, we have reproduced the
baseline generated from development of the simulator
[14]. Figure 2 illustrates the relevant cell populations
within the simulator under control conditions.
Although much is known on the mechanics of antigen-
presentation [15], it is unknown whether the individual
DC can simultaneously prime both encephalitogenic
CD4Th1 and Treg cell populations. If so, then key regula-
tory action might be taking place around the DCs that
prime these populations. The first experiment therefore
examined priming dynamics of CD8Treg cells in relation
to the antigenic peptide presentation by DCs to ascertain
whether an individual DC can prime both encephalito-
genic CD4Th1 and CD8Treg cells in parallel. The second
and third experiments investigate the manner that help (as
provided by CD4Treg cells) can modulate the regulatory
immune response. The time required for CD4Treg to
license the DC for Qa-1 expression, and spatial competi-
tion between CD4Treg and CD8Treg priming on the
same DC, may in fact have a limiting effect on the magni-
tude of the CD8Treg cytotoxic T lymphocyte (CTL)
response. In the control simulation, it takes approximetaly
60 hours for CD4Treg cells to mature into effectors and
license DCs for Qa-1 expression. Manipulation of the time
at which DCs express Qa-1 may affect the timing of
CD8Treg cell priming and activation, with earlier expres-
sion of Qa-1, permitting populations of CD8Treg cells
more time for proliferative activity within the lifetime of
DCs on which they prime. Similarly, manipulation of the
spatial competition between CD4Treg and CD8Treg cells
for binding space around DCs, may also affect CD8Treg
dynamics. Both CD4Treg and CD8Treg cells can prime
on the same DCs, and therefore compete for spatial access
to DC. Since CD4Treg cells may begin priming immedi-
ately upon DC maturation, with CD8Treg cells waiting for
the DC to be licensed, CD4Treg cells would be expected
to occupy a greater fraction of the total space around the
DC. If spatial competition is a limiting factor in CD8Treg
population expansion, then an increase in the competitive
strength shown by CD8Treg cells, would enhance the
resulting CTL response, as a greater number of CD8Treg
cells would be primed.
Results and discussion
Effective regulation does not require CD4Th1 and
CD8Treg to prime on the same DC
We examined the peptide presentation profiles for DCs
in silico using ARTIMMUS, and showed that the vast
majority (circa 90%) do not present antigenic peptides,
and of those that do, the overwhelming majority (circa
90%; or 9% of total DCs) present either MBP or TCR-
derived peptides, but not both. In fact, only 1% of DCs
within the simulation present both MBP and TCR-
derived peptides.
When imposing mutually exclusive presentation on
DCs (Figure 3), where a DC cannot simultaneously pre-
sent both MBP- and TCR-derived peptides, we find a
small reduction (A-Test score = 0.427) in the number of
DCs presenting TCR-derived peptides, and a small
increase in the number of DCs presenting MBP-derived
peptides (A-Test score = 0.635). This leads to an
approximate 10% reduction in the priming of CD8Treg
cells within the system, which leads to an approximate
5% reduction overall in the total number of CD4Th1
cells which are killed by the CD8Treg population. Next
we examined the effect of mutually exclusive presenta-
tion on priming DCs within the cervical lymph node
(CLN) where DCs prime both populations of T cells
(CD4Th1 and CD4Treg). We find a small, but not
scientifically significant, reduction in the CD4Th1 killing
facilitated by CD8Treg cells with respect to control
simulations (A-Test score for total CD4Th1 apoptosis =
0.415, and CD4Th1 apoptosis within the CLN = 0.44).
This indicates that enforcing mutually exclusive anti-
genic presentation has no scientifically significant effect
on the regulating capacity, and as such, we conjecture
that killing does not take place around the DC.
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Figure 2 Control dynamics of the ARTIMMUS simulator. Median population curves for effector CD4Th1, CD4Th2, CD4Treg and CD8Treg cells
as total numbers across all spatial compartments. CD4Th1 cells rapidly proliferate approximately 3-4 days following immunization for EAE,
peaking at approximately day 12. The population of CD4Treg cells begin to proliferate shortly before the peak in CD4Th1 cells is achieved. Due
to their helper function on CD8Treg cells, these show a similar proliferative timecourse, although having smaller total numbers. Although the
CD4Th2 cells compete with CD4Th1 cells and contribute to down-regulation of the autoimmune response, their total numbers are significantly
lower than the encephalitogenic CD4Th1 cells. The majority of CD4Treg and CD8Treg cells are primed within the spleen (data not presented),
and there are approximately 66% more CD4Treg than CD8Treg cells. The autoimmune response is complete and returns to a normal state
shortly after day 60 (after Read [14]).
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Figure 3 Mutually exclusive antigenic presentation by DCs. Median DC populations in a sample of 1,000 simulator runs. The graph shows
DC populations for control and mutually exclusive presentation experiments. Inspection of data (not shown) confirmed that mutually exclusive DC
simulation experiments resulted in no DCs presenting both MBP and TCR-derived peptides. A-Test scores showed a small effect size difference in
TCR-derived expression (score = 0.427) and MBP presentation (score = 0.635), although no real scientific significance, and virtually no effect size
difference in total DCs (score = 0.503) or cells presenting no antigen (score = 0.478).
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Timing of Qa-1 expression by dendritic cells modulates
the regulatory response
The control simulation uses two-way signalling between
DCs and CD4Treg cells. CD4Treg cells are activated
through a MHCII-Fr3 complex (signal 1), and once they
become effector cells, if a CD40-CD40L bind is also
formed (signal 2), the CD4Treg licenses the DC to express
Qa-1 (we have termed this help within the abstracted
model represented by the simulator). Expression of Qa-1
leads to the activation of CD8Treg cells (through cross-
priming by a Qa-1-CDR1/2 complex), and subsequent
apoptosis of CD4Th1 cells. This raises the question of
how variations in the timing of CD40-CD40L interactions
may modulate the CD8Treg CTL response.
The limiting nature of time required for DC licensing on
the CD8Treg response was investigated through delaying
the time upon which a DC can express Qa-1, and thus
gain the ability to prime CD8Treg cells (Figure 4, see
methods section for the derivation of this figure). In this
context, timing of Qa-1 expression, means the expression
of optimal levels of Qa-1/TCR-peptide complexes (along
with costimulatory molecules) on the surface of DCs
enabling the priming of the CD8Treg. This Qa-1 expres-
sion delay has been defined within the simulation as the
median time taken for a DC to become licensed by a
CD4Treg under control conditions (60 hours). We
removed the CD4Treg population from our experimental
simulations to allow manipulation of the time delay before
Qa-1 is constitutively expressed, and upregulate Qa-1
expression on DCs after a pre-specified period of time fol-
lowing their maturation. We demonstrate a medium-level
increase to the peak population of CD8Treg cells (relative
to the control dynamics) following the shorter delay in
Qa-1 expression (A-Test score = 0.704). Conversely, simu-
lations employing an increased delay to Qa-1 expression
(82 hours) demonstrate a large, and scientifically signifi-
cant, decrease in the peak population of CD8Treg cells
with respect to control dynamics (A-Test score = 0.163).
As would be expected, this demonstrates a large, and
scientifically significant decrease between the two delay
periods (A-Test score = 0.090). This indicates that the tim-
ing of Qa-1 expression by DCs has a significant affect on
modulating the regulatory CD8Treg CTL response.
Spatial competition between CD4Treg and CD8Treg cells
around the dendritic cell modulates the regulatory
response
Along with the temporal dynamics, the nature of help
from CD4Treg cells within this system also imposes a spa-
tial effect on CD8Treg priming. Simulations employing
modified CD8Treg spatial occupancy rules, which allow
CD8Treg cells to occupy space regardless of the CD4Treg
that may already reside there (see Figure 5), demonstrate
that the peak population of CD8Treg cells has undergone
a large, scientifically significant, increase relative to the
control simulation (A-Test score = 0.999). This indicates


















CD4Th1 (shorter delay)  
CD4Th2 (shorter delay)  
CD8Treg (shorter delay)  
CD4Th1 (longer delay)  
CD4Th2 (longer delay)  
CD8Treg (longer delay)  
Figure 4 Effect of the timing of Qa-1 expression on CD8Treg cell population. Median T cell effector populations in a sample of 1,000
simulator runs. The graph shows T cell effector populations with delayed Qa-1 expression on DC. The dashed curves reflect Qa-1 expression
using the shorter delay (60 hours), whilst the solid curves reflect Qa-1 expression using the longer delay (82 hours). There are no curves for the
CD4Treg populations as CD4Treg were abrogated in the simulation to facilitate the specific timing of Qa-1 expression by DCs.
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that spatial competition between CD4Treg and CD8Treg
cells has a significant effect on modulating the regulatory
CD8Treg CTL response.
Conclusions
We have sought to investigate, through simulation,
whether CD4Th1 and CD8Treg cells need to be primed
on the same DC, and whether temporal and spatial
mechanisms may regulate the CD8Treg CTL response
within EAE. As Beeston et al [16] have firmly established
that CD8Treg cells induce the killing of encephalitogenic
CD4Th1 cells, our first hypothesis was that a significant
degree of priming of these two cell populations occurs
simultaneously around the same DCs. Observation of DC
peptide presentation profiles has established that only
10% of DCs that are able to prime T cells simultaneously
prime both CD4Th1 and CD8Treg populations. Further-
more, given our criteria for scientifically significant
results, A-Test scores indicate that no significant differ-
ence in the ability of CD8Treg cells to regulate the
CD4Th1 population arises from this manipulation. We
therefore conclude that the killing of CD4Th1 cells as
induced by CD8Treg cells does not critically rely on
these T cell populations being primed on the same DCs,
and conjecture that it is probable that killing of CD4Th1
cells does not take place around the DC, as such we
reject the first hypothesis.
The second hypothesis concerned the timing of help
provided by CD4Treg cells, through the time at which
Qa-1 was expressed by DCs. We have found that delaying
Qa-1 expression by DCs has a significant effect on the
CD8Treg effector cell population. We therefore conclude
that the timing of Qa-1 expression by DCs modulates the
regulatory response, and as such accept the second age of
licensing hypothesis, that the time delay in licensing is sig-
nificant in modulating the regulatory CD8Treg CTL
response. The third hypothesis concerned the binding
space available around DCs, because although CD4Treg
cells license DCs to provide critical help for the recovery
from autoimmune response, their physical presence may
limit the size of this CD8Treg CTL response. By relaxing
spatial competition for CD8Treg, allowing them to occupy
space and gain access to DCs regardless of CD4Treg pre-
sence, we found a significant effect on the CD8Treg effec-
tor cell population. We therefore conclude that spatial
competition between CD4Treg and CD8Treg cells around
the DC modulates the regulatory response, and as such
accept the third spatial saturation hypothesis.
Results from the experiments regarding temporal
dynamics and spatial dynamics suggest that both factors
could serve to control the CTL response through altering
the size of the CD8Treg cell population. Through this
work, it is evident that although CD4Treg cells are
required as part of the regulatory response via their capa-
city to provide help, they also exert a restraining influ-
ence on the population size of CD8Treg cells by virtue of
their modulation of CD8Treg-DC interactions through
spatial competition. Although these results are grounded



























CD4Th1 (modified occupancy) 
CD4Th2 (modified occupancy) 
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Figure 5 Spatial dynamics of CD8Treg priming by DCs. Median T cell effector populations in a sample of 1,000 simulator runs. The graph
shows effector populations in two separate experiments: the solid curves are the results of running an experiment with modified CD8Treg
occupancy rules, the dashed curves are the results from a baseline experiment.
Williams et al. BMC Bioinformatics 2013, 14(Suppl 6):S9
http://www.biomedcentral.com/1471-2105/14/S6/S9
Page 6 of 9
specifically in the EAE system, we believe the spatial and
temporal constraints that CD4Th help (provided by
CD4Treg to CD8Treg in our simulation) imposes are
applicable to CTL responses in general, and have signifi-
cance in the design of treatments based on manipulating
the CTL response. For example, by providing artificial
help to DCs (through anti-CD40 antibodies) that prime
cytotoxic T cells, the CD4Th cell-imposed delay in licen-
sing can be removed, invoking an earlier CTL response
of larger magnitude. If the CD4Th population were to be
abrogated and suitable artificial cytokine and signalling
surrogates administered, the spatial restrictions that help
imposes, could be alleviated to effect a larger CTL
response.
Taken together the analysis from these experiments
show that CD4Th1 cells and Treg cells do not need to be
primed by the same DC in order for down-regulation of
the autoimmune response to occur. They have also
shown that regulation of CTL responses (through
CD8Treg cells within our simulation) appears to be lim-
ited by the nature of help provided by CD4Treg cells, and
the spatial competition that results around priming den-
dritic cells. Although simulation results cannot, as yet, be
confirmed using in vitro or in vivo testing, our work has
shown that temporal dynamics of Qa-1 expression and
spatial competition around DCs is very important for the
modulation of the CTL regulatory response.
Method
Simulation runs
The simulator (ARTIMMUS) was previously developed
[14] in Java and the MASON modelling and simulation
framework [17]. Within simulation runs, immunization is
through MBP, a myelin derivative, and adjuvant. CD4Th
cells are initially naive and start without a polarisation;
once polarised they make a probabilistic decision to
become either type1 or type2. This is affected by the cyto-
kine profiles present locally at the time of priming. The
adjuvant produces a type1 polarisation in DCs that per-
ceive them. Type 1 DCs secrete type1 cytokine, which
faciltate the majority of CD4Th cells to adopt a type1
polarisation upon their activation, with a small residual
number adopting a type2 polarisation. For the purposes of
statistical analysis, 1000 individual simulations for each
experiment were run on a server cluster. Matlab was used
to analyze cell populations and population level behavior.
Non-parametric A-tests
The ARTIMMUS simulator generates large volumes of
data for each simulation run. Non-parametric effect mag-
nitude tests [18,19], termed A-Tests, are used to measure
scientific significance (effect size) of the difference between
cell populations from simulation experiments with respect
to control cell populations. The A-Test provides a score in
the range [0.0, 1.0] that represents the probability that a
randomly selected sample from population one is larger
than a randomly selected sample from population two.
Vargha and Delaney [19] provide thresholds to indicate
the magnitude of difference between two populations.
They indicate scores >0.71 and <0.29 to represent large
differences, and we assume these boundaries to indicate
scientific significance. For completeness, they also indicate:
0.64< score <0.71 and 0.29< score <0.36 to represent
medium differences, and 0.50< score <0.56 and 0.44<
score <0.50 to represent small differences. We have cho-
sen to use a non-parametric test in order to avoid the
assumption that the underlying populations of simulator
results tend towards normality. We use an effect magni-
tude test to determine scientific significance in place of
statistical significance because with computer simulations,
a sufficiently large enough number of simulation runs can
always be performed, which will reveal a statistical signifi-
cance, unless the variable of interest truly has no effect.
We use the A-Test in preference to simply measuring the
difference in median values since the differences in med-
ians does not take the spread of the data into account (for
a more detailed justification please refer to Read et al
[20]). The A-Test was used to assess the significance of
experimental results with the control data.
Mutually exclusive peptide presentation by dendritic cells
The significance of antigenic peptide presentation by
DCs on the dynamics of CD8Treg priming was assessed.
To investigate peptide presentation dynamics, we have
manipulated ARTIMMUS such that presentation of anti-
genic peptide by DCs is mutually exclusive; DCs are no
longer able to present both MBP- and TCR-derived pep-
tides. This manipulation to ARTIMMUS allows DCs to
efferocytose cells as normal, however only the peptide
type (MBP- or TCR-derived) associated with the cell that
was first engulfed and processed into functional peptides,
can become presented on major histocompatibility com-
plexes (MHCs) of the DC. This negates the ability of a
single DC to prime both CD4Th1 and CD4Treg cells,
allowing us to observe the effects on the system. To
ensure individual DCs were only counted once, counts
were taken of DCs that had entered apoptosis by the end
of the simulation.
Temporal dynamics of CD8Treg priming by dendritic cells
The significance of the effect of the time at which Qa-1 is
expressed by DCs was assessed. Licensing of DCs to
express Qa-1 within the control simulation code is via
CD4Treg cells. In order to manipulate the time at which
Qa-1 is expressed, we abrogated CD4Treg cells from the
simulation, and to ensure continued priming of CD8Treg
cells we incorporated functionality for expression of Qa-1
by DCs, following specific time delays. In this context,
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timing of Qa-1 expression, means the expression of optimal
levels of Qa-1/TCR-peptide complexes (along with costi-
mulatory molecules) on the surface of DCs enabling the
priming of the CD8Treg.
A control experiment was performed to record the dis-
tribution of ages of DCs at their time of licensing. The
overall median age of licensing was calculated as 74
hours. An investigation of variation in DC age at time of
licensing showed that the overall age distribution could
be divided into two distinct sub-populations. The median
ages at the time of DC licensing for these two sub-popu-
lations were calculated as 60 hours and 82 hours [21].
These medians were used to parametrize enforced delays
in the Qa-1 expression by DCs. The division between the
two sub-populations related to DCs created before or
after day 20. This is the point in the simulation (see Fig-
ure 2 Control Dynamics) where the number of CD4Treg
cells and CD4Th1 cells are equal, with the CD4Treg cell
population rapidly increasing and the CD4Th1 cell popu-
lation rapidly decreasing.
Spatial dynamics of CD8Treg priming by dendritic cells
In a preliminary experiment we recorded the number and
nature of all T-cell neighbours of apoptotic DCs. From
this data we were able to ascertain a median number of
CD8Treg cells that were neighbours around a DC in a
control experiment in which the CD4Treg population
had been abrogated. We then used this number as an
upper limit for the number of CD8Treg cells that could
occupy a simulation grid space irrespective of how many
CD4Treg cells were currently resident in that space.
Using these modified CD8Treg occupancy rules, we ran
further baseline simulations to examine the effect of
reduced CD8Treg/CD4Treg spatial competition on
CD8Treg cell population size.
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